[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350688-105":59,"doc-detail-350688-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-clinical-value-of-adding-immune-checkpoint-inhibitors-to-radiotherapy-for-cancer-a-systematic-review-and-meta-analysis","The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer - a systematic review and meta-analysis","","Systematic review and meta-analysis evaluating randomized clinical trials that add immune checkpoint inhibitors (ICIs) to radiotherapy for cancer patients. PubMed, Embase, and Cochrane Library searches included English publications up to 14 April 2024; two independent reviewers screened studies and extracted hazard ratios and odds ratios. Fifteen trials (7947 patients) showed pooled benefits for overall survival and progression-free survival, especially in non-small-cell lung cancer and cervical cancer, with adjuvant scheduling supported despite increased grade 3+ adverse events.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-clinical-value-of-adding-immune-checkpoint-inhibitors-to-radiotherapy-for-cancer-a-systematic-review-and-meta-analysis/350688/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-clinical-value-of-adding-immune-checkpoint-inhibitors-to-radiotherapy-for-cancer-a-systematic-review-and-meta-analysis/350688.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question does the systematic review address?","Question",{"text":112,"@type":113},"It assesses the clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer by synthesizing randomized clinical trial evidence.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which main outcomes were analyzed in the meta-analysis?",{"text":117,"@type":113},"Overall survival and progression-free survival were evaluated using hazard ratios, and objective response rate, disease control rate, and adverse events were evaluated using odds ratios.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key results on efficacy and safety?",{"text":121,"@type":113},"Pooled estimates indicated improved overall survival and progression-free survival overall, with significant benefits reported for non-small-cell lung cancer and cervical cancer. The incidence of grade 3 or higher treatment-related and immune-related adverse events increased.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350688,1790211786,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","AnnAls of Medicine  \n2026, Vol. 58, no. 1, 2619281  \n[https://doi.org/10.1080/07853890.2026.2619281](https://doi.org/10.1080/07853890.2026.2619281)  \nRESEARCH ARTICLE     \nThe clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis  \nKun Liua , Youwen Zhua  and Hong Zhua,b   \nadepartment of oncology, Xiangya Hospital, central south University, changsha, Hunan, china; bnational clinical Research center for Geriatric disorders, Xiangya Hospital, central south University, changsha, Hunan, china  \nABSTRACT  \nBackground: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. Methods: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the included studies and extracted relevant data, then selected the random or fixed-effects model based on the I2 statistic. The main outcomes were hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS); Odds ratios (ORs) with 95% CIs for objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Stratified analysis was performed based on cancer type, ICI type, and the timing of ICI addition. The study was registered on PROSPERO (CRD42024551008).  \nResults: 15 RCTs with 7947 patients were included. Pooled HRs were 0.865 (95% CI, 0.730–1.000; I2 = 72. 1%) for OS and 0.799 (0.677–0.922; I2 = 82.0%) for PFS in cancer patients. In cancer types, adding immunotherapy to radiotherapy significantly improved patients with non-small-cell lung cancer (OS: 0.544 [0.371–0.717]; PFS: 0.527 [0.438– 0.617]) and cervical cancer (OS: 0.722 [0.578–0.867] and PFS: 0.754 [95%CI, 0.621–0.887]). Regarding the ICIs schedule, adjuvant ICI therapy with pooled HRs was 0.742 (0.649– 0.834) for OS and 0.638 (0.579–0.697) for PFS. In addition, the pooled ORs for the incidence of grade 3 or higher treatment-related and immune-related adverse events were 1.227 (1.059–1.421; I2 = 71.9%) and 2.217 (1.743–2.821; I2 = 74.0%), respectively. Conclusion: Adding immunotherapy to radiotherapy can provide significant clinical benefits for patients with NSCLC and cervical cancer, and the addition of these ICIs in the adjuvant stage is supported.  \n1. Introduction  \nARTICLE HISTORY  \nReceived 25 June 2025 Accepted 15 January 2026  \nKEYWORDS  \nOncology;  \nimmunotherapy;  \nradiotherapy; efficacy; sequencing; meta-analysis  \nCancer constitutes a substantial global economic and health burden, evidenced by an estimated 20 million new diagnoses and 9.7 million mortalities in 2022 alone [1,2] . This epidemiological reality underscores the urgent necessity for advancing antitumor therapeutic strategies [3] . Standard oncological modalities primarily encompass surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy [4] . Notably, radiotherapy is utilized in the management of over 60% of cancer patients globally [5–7] . However, immune checkpoint inhibitor (ICI) monotherapy frequently fails to elicit a satisfactory objective response rate (ORR) . For instance, cemiplimab in recurrent cervical cancer, the ORR for the cemiplimab group and the chemotherapy group in the total population were 16.4 and 6.3%, respectively [8] . Therefore, radiotherapy is increasingly employed as a synergistic adjunct to immunotherapy to enhance therapeutic efficacy [9, 10] .  \nCONTACT Hong Zhu  [zhuhong719@csu.edu.cn](zhuhong719@csu.edu.cn)  department of oncology, Xiangya Hospital, central south University, changsha, Hunan410008, china  \n supplemental data for this article is available online at [https://doi.org/10.1080/07853890","cbCaiaSYuL8qHQWf","https://ap.wps.com/l/cbCaiaSYuL8qHQWf","pdf",1912026,16,"English","# ABSTRACT\n# 1. Introduction","[{\"question\":\"What clinical question does the systematic review address?\",\"answer\":\"It assesses the clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer by synthesizing randomized clinical trial evidence.\"},{\"question\":\"Which main outcomes were analyzed in the meta-analysis?\",\"answer\":\"Overall survival and progression-free survival were evaluated using hazard ratios, and objective response rate, disease control rate, and adverse events were evaluated using odds ratios.\"},{\"question\":\"What were the key results on efficacy and safety?\",\"answer\":\"Pooled estimates indicated improved overall survival and progression-free survival overall, with significant benefits reported for non-small-cell lung cancer and cervical cancer. The incidence of grade 3 or higher treatment-related and immune-related adverse events increased.\"}]","The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer - a systematic review and meta-analysis | PDF",1790090617,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efd4987a60ca6eaaa8095eae0c32e460.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ce8c83f94d26366dfdd89a560fd3718.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a96bbad39ecfb41efcca167a4507417.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1a8eed3cf50a835115c6685ffb3a680.webp",980,1306]